

## Product Data Sheet

Product Name: LHF-535

Cat. No.: GC65001

### Chemical Properties

Cas. No. 1450929-77-7


Formula C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub> M.Wt 412.52

Solubility DMSO : 96.67 mg/mL (234.34 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



### Background

LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC<sub>50</sub>s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively[1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

---

LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses. LHF-535 inhibits Lassa GP-pseudotyped lentivirus with an IC<sub>50</sub> of 0.1-0.3 nM[2].

LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protects mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver[2]. An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection, demonstrating that LHF-535 is efficacious as a post-exposure therapeutic in mice[2].

[1]. Dongcheng Dai, et al. Antiviral drugs for treatment of arenavirus infection. WO2013123215A2.

[2]. Madu IG, et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: [tech@glpbio.com](mailto:tech@glpbio.com)

Address: 10292 Central Ave. #205, Montclair, CA, USA